Regeneron Pharmaceuticals (REGN) Total Debt: 2020-2025
Historic Total Debt for Regeneron Pharmaceuticals (REGN) over the last 6 years, with Sep 2025 value amounting to $2.0 billion.
- Regeneron Pharmaceuticals' Total Debt rose 0.10% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 0.10%. This contributed to the annual value of $2.0 billion for FY2024, which is 0.08% up from last year.
- Regeneron Pharmaceuticals' Total Debt amounted to $2.0 billion in Q3 2025, which was up 0.05% from $2.0 billion recorded in Q2 2025.
- In the past 5 years, Regeneron Pharmaceuticals' Total Debt ranged from a high of $2.0 billion in Q3 2025 and a low of $2.0 billion during Q1 2021.
- Moreover, its 3-year median value for Total Debt was $2.0 billion (2024), whereas its average is $2.0 billion.
- Data for Regeneron Pharmaceuticals' Total Debt shows a peak YoY spiked of 31.95% (in 2021) over the last 5 years.
- Over the past 5 years, Regeneron Pharmaceuticals' Total Debt (Quarterly) stood at $2.0 billion in 2021, then climbed by 0.07% to $2.0 billion in 2022, then climbed by 0.08% to $2.0 billion in 2023, then grew by 0.08% to $2.0 billion in 2024, then climbed by 0.10% to $2.0 billion in 2025.
- Its Total Debt was $2.0 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $2.0 billion in Q1 2025.